Special Issue

State-of-the-Art Drug Delivery in Europe

Message from the Guest Editors

Nowadays, modern strategies in healthcare involve the development of drug delivery systems for targeted therapy and controlled drug release to improve clinical outcomes. The safety and effectiveness of many innovative delivery systems containing synthetic active substances or natural compounds, especially macromolecules, are being investigated. These innovative systems are developed based on a wealth of knowledge in the fields of pharmaceutical, medicine and engineering. For this Special Issue, the authors are invited to present a wide range of topics on drug delivery including recent advances in the design and fabrication of health products, natural product-based delivery systems, and characterization of their efficiency and safety profile based on in vitro or in vivo studies. For this Special Issue, we are soliciting the submission of original articles or review articles from researchers based in Europe, where the main focus of the article is research carried out in the field of drug delivery.

Guest Editors

Dr. Anca-Maria Arseniu

Dr. Adriana Aurelia Chiş

Dr. Luca-Liviu Rus

Dr. Claudiu Morgovan

Dr. Jean A. Boutin

Deadline for manuscript submissions

closed (31 January 2024)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/127194

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).